Advertisement

Inflammation

pp 1–13 | Cite as

Semaphorin 3F Promotes Transendothelial Migration of Leukocytes in the Inflammatory Response After Survived Cardiac Arrest

  • Stephanie Reichert
  • Stefanie Scheid
  • Tina Roth
  • Marius Herkel
  • Diana Petrova
  • Alexandra Linden
  • Miki Weberbauer
  • Jennifer Esser
  • Philipp Diehl
  • Sebastian Grundmann
  • Hans-Jörg Busch
  • Katrin Fink
  • Christoph Bode
  • Martin Moser
  • Thomas HelbingEmail author
ORIGINAL ARTICLE
  • 31 Downloads

Abstract

Leukocyte transmigration through the blood vessel wall is a fundamental step of the inflammatory response and requires expression of adhesion molecule PECAM-1. Accumulating evidence implicates that semaphorin (Sema) 3F and its receptor neuropilin (NRP) 2 are central regulators in vascular biology. Herein, we assess the role of Sema3F in leukocyte migration in vitro and in vivo. To determine the impact of Sema3F on leukocyte recruitment in vivo, we used the thioglycollate-induced peritonitis model. After the induction of peritonitis, C57BL/6 mice were intraperitoneally (i.p.) injected daily with recombinant Sema3F or solvent for 3 days. Compared with solvent-treated controls, leukocyte count was increased in the peritoneal lavage of Sema3F-treated mice indicating that Sema3F promotes leukocyte extravasation into the peritoneal cavity. In line with this observation, stimulation of human endothelial cells with Sema3F enhanced the passage of peripheral blood mononuclear cells (PBMCs) through the endothelial monolayer in the transwell migration assays. Conversely, silencing of endothelial Sema3F by siRNA transfection dampened diapedesis of PBMCs through the endothelium in vitro. xMechanistically, Sema3F induced upregulation of adhesion molecule PECAM-1 in endothelial cells and in murine heart tissue shown by immunofluorescence and western blotting. The inhibition of PECAM-1 by blocking antibody HEC7 blunted Sema3F-induced leukocyte migration in transwell assays. SiRNA-based NRP2 knockdown reduced PECAM-1 expression and migration of PBMCs in Sema3F-treated endothelial cells, indicating that PECAM-1 expression and leukocyte migration in response to Sema3F depend on endothelial NRP2. To assess the regulation of Sema3F in human inflammatory disease, we collected serum samples of patients from day 0 to day 7 after survived out-of-hospital cardiac arrest (OHCA, n = 41). First, we demonstrated enhanced migration of PBMCs through endothelial cells exposed to the serum of patients after OHCA in comparison to the serum of patients with stable coronary artery disease or healthy volunteers. Remarkably, serum samples of OHCA patients contained significantly higher Sema3F protein levels compared with CAD patients (CAD, n = 37) and healthy volunteers (n = 11), suggesting a role of Sema3F in the pathophysiology of the inflammatory response after OHCA. Subgroup analysis revealed that elevated serum Sema3F levels after ROSC are associated with decreased survival, myocardial dysfunction, and prolonged vasopressor therapy, clinical findings that determine the outcome of post-resuscitation period after OHCA. The present study provides novel evidence that endothelial Sema3F controls leukocyte recruitment through a NRP2/PECAM-1-dependent mechanism. Sema3F serum concentrations are elevated following successful resuscitation suggesting that Sema3F might be involved in the inflammatory response after survived OHCA. Targeting the Sema3F/NRP2/PECAM-1 pathway could provide a novel approach to abolish overwhelming inflammation after resuscitation.

KEY WORDS

inflammation leukocyte transmigration semaphorin 3F neuropilin-2 PECAM-1 

Notes

Acknowledgements

We are indebted to Jessica Beckert for her outstanding technical assistance.

Funding

This work was supported by the Deutsche Forschungsgemeinschaft to T. H. (HE 7432/1-1) and to M. M. (973/8-1).

Compliance with Ethical Standards

All procedures performed in studies involving murine or human tissues were in accordance with the ethical standards of the institution and/or national research.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Muller, W.A. 2009. Mechanisms of transendothelial migration of leukocytes. Circulation Research 105 (3): 223–230.Google Scholar
  2. 2.
    Ley, K., et al. 2007. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nature Reviews. Immunology 7 (9): 678–689.Google Scholar
  3. 3.
    Muller, W.A. 1995. The role of PECAM-1 (CD31) in leukocyte emigration: studies in vitro and in vivo. Journal of Leukocyte Biology 57 (4): 523–528.Google Scholar
  4. 4.
    Muller, W.A. 2016. Transendothelial migration: unifying principles from the endothelial perspective. Immunological Reviews 273 (1): 61–75.Google Scholar
  5. 5.
    Muller, W.A., et al. 1993. PECAM-1 is required for transendothelial migration of leukocytes. The Journal of Experimental Medicine 178 (2): 449–460.Google Scholar
  6. 6.
    Mamdouh, Z., et al. 2003. Targeted recycling of PECAM from endothelial surface-connected compartments during diapedesis. Nature 421 (6924): 748–753.Google Scholar
  7. 7.
    Dasgupta, B., et al. 2009. A novel and critical role for tyrosine 663 in platelet endothelial cell adhesion molecule-1 trafficking and transendothelial migration. Journal of Immunology 182 (8): 5041–5051.Google Scholar
  8. 8.
    Epstein, J.A., H. Aghajanian, and M.K. Singh. 2015. Semaphorin signaling in cardiovascular development. Cell Metabolism 21 (2): 163–173.Google Scholar
  9. 9.
    Sahay, A., et al. 2003. Semaphorin 3F is critical for development of limbic system circuitry and is required in neurons for selective CNS axon guidance events. The Journal of Neuroscience 23 (17): 6671–6680.Google Scholar
  10. 10.
    Zhang, H., et al. 2018. Understanding netrins and semaphorins in mature endothelial cell biology. Pharmacological Research 137: 1–10.Google Scholar
  11. 11.
    Neufeld, G., et al. 2007. Semaphorin signaling in vascular and tumor biology. Advances in Experimental Medicine and Biology 600: 118–131.Google Scholar
  12. 12.
    Bielenberg, D.R., et al. 2004. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. The Journal of Clinical Investigation 114 (9): 1260–1271.Google Scholar
  13. 13.
    Buehler, A., et al. 2013. Semaphorin 3F forms an anti-angiogenic barrier in outer retina. FEBS Letters 587 (11): 1650–1655.Google Scholar
  14. 14.
    Coma, S., et al. 2010. Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F. Cancer Research 70 (9): 3823–3832.Google Scholar
  15. 15.
    Coma, S., A. Shimizu, and M. Klagsbrun. 2011. Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2. Cell Adhesion & Migration 5 (3): 266–275.Google Scholar
  16. 16.
    Gaur, P., et al. 2009. Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clinical Cancer Research 15 (22): 6763–6770.Google Scholar
  17. 17.
    Yuan, L., et al. 2002. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129 (20): 4797–4806.Google Scholar
  18. 18.
    Nakayama, H., et al. 2015. Regulation of mTOR Signaling by Semaphorin 3F-Neuropilin 2 Interactions In Vitro and In Vivo. Scientific Reports 5: 11789.Google Scholar
  19. 19.
    Heinke, J., et al. 2008. BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis. Circulation Research 103 (8): 804–812.Google Scholar
  20. 20.
    Bogen, S., et al. 1994. Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo. The Journal of Experimental Medicine 179 (3): 1059–1064.Google Scholar
  21. 21.
    Fink, K., et al. 2015. Selenium prevents microparticle-induced endothelial inflammation in patients after cardiopulmonary resuscitation. Critical Care 19: 58.Google Scholar
  22. 22.
    Adrie, C., et al. 2002. Successful cardiopulmonary resuscitation after cardiac arrest as a “sepsis-like” syndrome. Circulation 106 (5): 562–568.Google Scholar
  23. 23.
    Bro-Jeppesen, J., et al. 2017. Level of systemic inflammation and endothelial injury is associated with cardiovascular dysfunction and vasopressor support in post-cardiac arrest patients. Resuscitation 121: 179–186.Google Scholar
  24. 24.
    Suzuki, K., A. Kumanogoh, and H. Kikutani. 2008. Semaphorins and their receptors in immune cell interactions. Nature Immunology 9 (1): 17–23.Google Scholar
  25. 25.
    Mirakaj, V., and P. Rosenberger. 2017. Immunomodulatory functions of neuronal guidance proteins. Trends in Immunology 38 (6): 444–456.Google Scholar
  26. 26.
    Morote-Garcia, J.C., et al. 2012. Endothelial semaphorin 7A promotes neutrophil migration during hypoxia. Proceedings of the National Academy of Sciences of the United States of America 109 (35): 14146–14151.Google Scholar
  27. 27.
    Roth, J.M., et al. 2016. Semaphorin 7A aggravates pulmonary inflammation during lung injury. PLoS One 11 (1): e0146930.Google Scholar
  28. 28.
    Rienks, M., et al. 2017. Sema3A promotes the resolution of cardiac inflammation after myocardial infarction. Basic Research in Cardiology 112 (4): 42.Google Scholar
  29. 29.
    Bielenberg, D.R., A. Shimizu, and M. Klagsbrun. 2008. Semaphorin-induced cytoskeletal collapse and repulsion of endothelial cells. Methods in Enzymology 443: 299–314.Google Scholar
  30. 30.
    Clarhaut, J., et al. 2009. ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells. Neoplasia 11 (2): 157–166.Google Scholar
  31. 31.
    Geretti, E., A. Shimizu, and M. Klagsbrun. 2008. Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis 11 (1): 31–39.Google Scholar
  32. 32.
    Mendes-da-Cruz, D.A., et al. 2014. Semaphorin 3F and neuropilin-2 control the migration of human T cell precursors. PLoS One 9 (7): e103405.Google Scholar
  33. 33.
    Immormino, R.M., et al. 2018. Neuropilin-2 regulates airway inflammatory responses to inhaled lipopolysaccharide. American Journal of Physiology. Lung Cellular and Molecular Physiology 315 (2): L202–L211.Google Scholar
  34. 34.
    Romer, L.H., et al. 1995. IFN-gamma and TNF-alpha induce redistribution of PECAM-1 (CD31) on human endothelial cells. Journal of Immunology 154 (12): 6582–6592.Google Scholar
  35. 35.
    Rival, Y., et al. 1996. Inhibition of platelet endothelial cell adhesion molecule-1 synthesis and leukocyte transmigration in endothelial cells by the combined action of TNF-alpha and IFN-gamma. Journal of Immunology 157 (3): 1233–1241.Google Scholar
  36. 36.
    Hebeda, C.B., et al. 2008. In vivo blockade of Ca(+2)-dependent nitric oxide synthases impairs expressions of L-selectin and PECAM-1. Biochemical and Biophysical Research Communications 377 (2): 694–698.Google Scholar
  37. 37.
    Gumina, R.J., et al. 1997. Characterization of the human platelet/endothelial cell adhesion molecule-1 promoter: identification of a GATA-2 binding element required for optimal transcriptional activity. Blood 89 (4): 1260–1269.Google Scholar
  38. 38.
    Hossain, M., et al. 2015. Endothelial LSP1 modulates extravascular neutrophil chemotaxis by regulating nonhematopoietic vascular PECAM-1 expression. Journal of Immunology 195 (5): 2408–2416.Google Scholar
  39. 39.
    Coma, S., et al. 2013. GATA2 and Lmo2 control angiogenesis and lymphangiogenesis via direct transcriptional regulation of neuropilin-2. Angiogenesis 16 (4): 939–952.Google Scholar
  40. 40.
    Coute, R.A., et al. 2017. National Institutes of Health-funded cardiac arrest research: a 10-year trend analysis. Journal of the American Heart Association 6 (7): e005239.Google Scholar
  41. 41.
    Grasner, J.T., et al. 2016. EuReCa ONE-27 Nations, ONE Europe, ONE Registry: a prospective one month analysis of out-of-hospital cardiac arrest outcomes in 27 countries in Europe. Resuscitation 105: 188–195.Google Scholar
  42. 42.
    Sasson, C., et al. 2010. Predictors of survival from out-of-hospital cardiac arrest: a systematic review and meta-analysis. Circulation. Cardiovascular Quality and Outcomes 3 (1): 63–81.Google Scholar
  43. 43.
    Nolan, J.P., et al. 2015. European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015: Section 5 of the European Resuscitation Council Guidelines for Resuscitation 2015. Resuscitation 95: 202–222.Google Scholar
  44. 44.
    Huang, C.H., et al. 2016. Predicting the outcomes for out-of-hospital cardiac arrest patients using multiple biomarkers and suspension microarray assays. Scientific Reports 6: 27187.Google Scholar
  45. 45.
    Peberdy, M.A., et al. 2016. Inflammatory markers following resuscitation from out-of-hospital cardiac arrest-A prospective multicenter observational study. Resuscitation 103: 117–124.Google Scholar
  46. 46.
    Huet, O., et al. 2011. Postresuscitation syndrome: potential role of hydroxyl radical-induced endothelial cell damage. Critical Care Medicine 39 (7): 1712–1720.Google Scholar
  47. 47.
    Fink, K., et al. 2010. Severe endothelial injury and subsequent repair in patients after successful cardiopulmonary resuscitation. Critical Care 14 (3): R104.Google Scholar
  48. 48.
    Bro-Jeppesen, J., et al. 2016. Endothelial activation/injury and associations with severity of post-cardiac arrest syndrome and mortality after out-of-hospital cardiac arrest. Resuscitation 107: 71–79.Google Scholar
  49. 49.
    Johansson, P.I., et al. 2015. Sympathoadrenal activation and endothelial damage are inter correlated and predict increased mortality in patients resuscitated after out-of-hospital cardiac arrest. a post hoc sub-study of patients from the TTM-trial. PLoS One 10 (3): e0120914.Google Scholar
  50. 50.
    Ranganathan, P., et al. 2014. Semaphorin 3A inactivation suppresses ischemia-reperfusion-induced inflammation and acute kidney injury. American Journal of Physiology. Renal Physiology 307 (2): F183–F194.Google Scholar
  51. 51.
    Konig, K., et al. 2016. Inhibition of plexin C1 protects against hepatic ischemia-reperfusion injury. Critical Care Medicine 44 (8): e625–e632.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Stephanie Reichert
    • 1
  • Stefanie Scheid
    • 1
  • Tina Roth
    • 1
  • Marius Herkel
    • 1
  • Diana Petrova
    • 1
  • Alexandra Linden
    • 1
  • Miki Weberbauer
    • 1
  • Jennifer Esser
    • 1
  • Philipp Diehl
    • 1
  • Sebastian Grundmann
    • 1
  • Hans-Jörg Busch
    • 2
  • Katrin Fink
    • 2
  • Christoph Bode
    • 1
  • Martin Moser
    • 1
  • Thomas Helbing
    • 1
    Email author
  1. 1.Department of Cardiology and Angiology IHeart Center Freiburg University, Faculty of Medicine, University of FreiburgFreiburg im BreisgauGermany
  2. 2.Department of Emergency MedicineUniversity Hospital of Freiburg, Faculty of Medicine, University of FreiburgFreiburg im BreisgauGermany

Personalised recommendations